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The Year of the Niche
Schofield’s concept of the stem cell niche may be almost 30 years old, but this year has seen a remarkable number of
publications exploring the regulatory relationships between stem cells and their surrounding environment. Two papers
in this issue, from the groups of Jacobsen and Suda, examine the influence of thrombopoietin on the regulation of HSC
function and quiescence, and implicate osteoblastic cells with an additional role as a component of the stem cell niche.
The stem cell niche model has also extended into the realm of cancer biology. Covering this concept, we include in this
issue a minireview article from Sneddon and Werb to overview the growing evidence that tumors arising from a subset
of stem-like cells may also depend on specific cues from the microenvironment.
What’s in a Method?
In the second article published in our ‘‘Protocol Reviews’’ format, Rakic and colleagues critically
review the expansive literature concerning the identification, and potential misidentification, of
adult neural progenitors. This article highlights many of the experimental pitfalls that can cloud
interpretations, and highlights combinations of more modern techniques that may lend consis-
tency to a discipline that has been prone to variability. In another controversial field, Kovacic,
Harvey, and Dimmeler provide an insightful commentary about the landscape facing cardiovas-
cular regenerative medicine in their meeting report of a recent NIH-NHLBI Symposium. Among
other points, the authors indicate that delegates advocated for inclusion of more descriptive
methodological details in published manuscripts. Given the expanding community of stem
cell researchers across the globe, combined with the extension of a range of assays across var-
ious disciplines of stem cell research, it is essential to establish a forum for the explanation and
critique of experimental nuances. We at Cell Stem Cell encourage the submission of additional
protocol reviews toward this goal.
Cell Progenitor Cell
Can progenitor cell studies inform us about stem cell biology? It can be difficult to draw lines
between studies that add insight solely into precursor activity and others in which observa-
tions of stem cell progeny may also reveal traits specific to the parental stem cell compart-
ment. Two different reports in this issue fall into the latter category. In one, the Hattori
laboratory reveals that in the absence of fibrinolytic activation during myeloablative stress,
hematopoietic progenitors are unable to replace depleted blood cells. In the other, the
Weissman group uses combinations of surface proteins to isolate hierarchical fractions of hu-
man hematopoietic progenitors.While quite distinct, both studies underscore the importance
of establishingmodel systemswith which to isolate, and examine the function of cells beyond
those with long-term repopulating ability. To this end, a recent Resource article from Goodell
and colleagues compared subsets of stem and progenitor cells and detected ‘‘fingerprints’’
that distinguished them, highlighting that stem cell-specific properties may only become
apparent when observed relative to non-stem populations.
One Small Step, or One Giant Leap?
The media frenzy that met our publication of one of the three papers (Maherali et al.) revealing the functional capacity of
murine induced pluripotent (iPS) cells has now been dwarfed by the attention showered on the Yamanaka and Thomson
laboratories for demonstrating the same principle in human cells. The observation that the same four proteins can convert
both mouse and human fibroblasts into seemingly pluripotent, ES-like cells is even more astounding considering that al-
ternate ‘‘cocktail’’ components seem to do the trick as well. In his Preview in this issue, Ian Wilmut combines unabashed
enthusiasm for the implications of human iPS cell generation with an appropriately cautious note regarding the remaining
hurdles facing the field prior to clinical applications of directly reprogrammed cells. In the meantime, progress toward stem
cell-based treatment of disease continues to advance using somatic stem cell populations. As an example, the Torrente lab
provides a proof of principle in this issue in which amousemodel ofmuscular dystrophy can be improved by transplantation
of purified progenitor cells derived from Duchenne muscular dystrophy patients following genetic correction of the cells via
‘‘exon skipping.’’ It has been an exciting year for stem cells, and Cell Stem Cell is pleased to have been a part of it. We all
look forward to many more dramatic advances in the months and years to come.Cell Stem Cell 1, December 2007 ª2007 Elsevier Inc. xi
